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Lung cancer is the leading cause of cancer death in the
United States, with more than 158,000 deaths expected
in 2015, approximately 90% of which will have been
caused by cigarette smoking. Worldwide in 2012, there
were 1,589,800 deaths from lung cancer. Cigarette
smoking accounts for 80% of the worldwide lung can-
cer burden in males and at least 50% in females. Our
approach to lung cancer prevention is based on an
understanding of the carcinogens in tobacco smoke and
their mechanisms of action. This leads to carcinogen
and toxicant biomarkers that have the potential to
identify susceptible individuals at a young age so they
can be targeted for intensive smoking cessation therapy
and surveillance. We have developed a panel of urinary
tobacco smoke carcinogen and toxicant metabolites that
can be used to quantify exposure in cigarette smokers.
The panel consists of nicotine metabolites comprising
nearly 90% of the nicotine dose (nicotine, cotinine, 3’-
hydroxycotinine and their glucuronides, and nicotine-
N-oxide), total NNAL (comprised of free NNAL and its
glucuronides – metabolites of the tobacco-speciﬁc lung
carcinogen NNK), total NNN (comprised of free NNN
and its glucuronides – metabolites of the tobacco-
speciﬁc carcinogen NNN), phenanthrene tetraol and
3’-hydroxyphenanthrene (metabolites of the represen-
tative polycyclic aromatic hydrocarbon phenanthrene),
mercapturic acid metabolites of the volatile toxicants
and carcinogens 1,3-butadiene, acrolein, crotonalde-
hyde, and benzene, 8-iso-PGF2a (a representativeF2-isoprostane resulting from oxidative damage), and
PGEM, a prostaglandin E2 metabolite related to
inﬂammation. Multiple studies by our group and others
have clearly demonstrated that this panel of metabo-
lites is related to exposure to tobacco smoke. Thus,
most of these metabolites decrease upon cessation of
cigarette smoking. We have participated in collabora-
tive prospective epidemiologic studies to determine
whether these urinary biomarkers are also related to
lung cancer risk. The Shanghai Cohort Study of 18,244
Chinese men collected and stored urine samples in the
1980s. We analyzed urine samples from 325 lung can-
cer cases and 356 controls, all smokers from this study,
and found that the smoking-adjusted odds ratios (95%
CIs) for lung cancer for the highest relative to the
lowest quartile of urinary total nicotine, total cotinine,
total 3’-hydroxycotinine, total nicotine equivalents and
total NNAL were 3.03 (1.80-5.10), 4.70 (2.61-8.46),
4.26 (2.37-7.68), 4.71 (2.61-8.52), and 3.15 (1.86-5.33),
respectively (all Ptrend <0.001). We have also found that
phenanthrene tetraol, but not the mercapturic acid
metabolites of the volatile toxicants and carcinogens, is
independently related to lung cancer risk among
smokers in this study. These results demonstrate that
these urinary metabolites are risk biomarkers as well
as exposure biomarkers.
We have also used these biomarkers to investigate
potential explanations for differing risks of lung cancer
among ethnic groups. The Multiethnic Cohort Study
demonstrated that, for the same number of cigarettes
smoked, African Americans and Native Hawaiians have a
higher risk for lung cancer than Whites while Latinos and
Japanese Americans have a lower risk. We analyzed urine
samples from 300-700 subjects per group for total nico-
tine equivalents, total NNAL, phenanthrene tetraol, 3-
hydroxyphenanthrene, and the mercapturic acids of
acrolein, crotonaldehyde, and benzene. The results
demonstrated that African Americans, although smoking
fewer cigarettes per day than any of the other groups
except Latinos, had signiﬁcantly higher levels of total
nicotine equivalents, total NNAL, phenanthrene tetraol, 3-
hydroxyphenanthrene, and the benzene metabolite S-
phenylmercapturic acid compared to Whites while Japa-
nese Americans had signiﬁcantly lower levels of total
nicotine equivalents, total NNAL, and 3-hydroxyphenan-
threne than Whites. The relatively low levels of total
nicotine equivalents in the urine of the Japanese Amer-
ican smokers was related to low activity polymorphisms
in CYP2A6, the major enzyme responsible for nicotine
metabolism. These results partially explain the differing
susceptibilities to lung cancer among these ethnic groups,
but further research is necessary to fully understand the
relatively high risk of Native Hawaiians (which may be
related to their acrolein levels) or the low risk of Latinos.
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are risk biomarkers for lung cancer in these studies, they
are not fully predictive. This is because these biomarkers
are mainly measuring exposure but do not take into ac-
count the critical metabolic activation step leading to the
formation of DNA adducts which cause the multiple
mutations observed in lung cancer. Quantitation of DNA
adducts is challenging because of their low levels, typi-
cally less than 1 adduct per 107 normal bases, and the
small amounts of DNA available for studies in living
humans. To address this question, we are developing high
resolution mass spectrometric methods for quantifying
oral cell DNA adducts as a surrogate for DNA adduct
formation in the lung. In one recent study, we found
remarkably high levels of DNA adducts of tobacco-
speciﬁc compounds in in the oral mucosa cells of smokers
compared to non-smokers. We are also able to quantify
formaldehyde-DNA adducts in oral mucosa cells. As mass
spectrometric methods for analysis of carcinogen-DNA
adducts become increasingly more sensitive and speciﬁc,
it appears likely that quantitation of a panel of tobacco
carcinogen DNA adducts in smokers, leading to identiﬁ-
cation of susceptible individuals, may be feasible.
Targeting PD1 and PDL1 in lung cancer
treatment: Where are we now?Roy S. Herbst Yale Cancer Center,
New Haven, CTThe therapy for advanced non-small cell lung cancer has
improved dramatically in recent years. We have moved
from an era of Cisplatin-based chemotherapy to the use
of targeted therapy, immunotherapy, and their combi-
nations. Of equal importance is the evolution of more
personalized tissue-based therapy used to guide choice.
This lecture will chronicle the 10+ year history of the
development of biopsy-based treatments for lung cancer,
evolving from the initial BATTLE trials to the Umbrella
and Master Protocols of today. The dawn of immuno-
therapy will be discussed along with efforts designed to
administer it in a more targeted way with the develop-
ment of novel biomarker and combinations.
Beyond monotherapy: Integrating
immunotherapy into current
treatment regimensKaren L. Kelly University of California, Davis,
Sacramento, CAImmunotherapy strategies targeting immune checkpoints
including PD-1, PDL-1, and CTLA-4, have garneredsubstantial enthusiasm after demonstrating clinical ac-
tivity in a broad spectrum of tumor types. In metastatic
non-small cell lung cancer (NSCLC) two randomizedphase
III trials have convincingly shown an overall survival
beneﬁt in patients receiving nivolumab in the second line
setting. The ﬁrst trial conducted in patients with squa-
mous cell histology randomized 272 patients to receive
nivolumab or docetaxel (1). The HR for OS was 0.59 (95%
CI 0.44-0.79; p<0.001). The median survival times were
9.2 months for nivoulmab and 6.0 months for docetaxel.
In the second trial performed in 582 patients with
nonsquamous cell histology nivolumab was again shown
to be superior to docetaxel with an OS HR 0.73 (95% CI
0.59-0.88; p¼0.002) and a median survival time of 12.2
months for nivoulmab and 9.4 months for docetaxel (2).
Two additional randomized trials comparing docetaxel
to pembrolizumab (anti PD-L inhibitor) or atezolizumab
(anti PDL-1 inhibitor) have completed accrual and are
likely to favor the immunotherapy arm. The efﬁcacy and
mild, non-overlapping toxicity proﬁle of immune
checkpoint inhibitors make them an ideal partner to
combine with systemic agents such as cytotoxic
chemotherapy, molecularly targeted agents and other
immune therapies in an effort to further prolong
survival for patients with advanced lung cancer.
Combinations with cytotoxic chemotherapy. The ratio-
nale for evaluating chemotherapy with immune check-
point inhibitors include: 1) tumor cell death from
conventional therapies releases neo-antigens into the
microenvironment leading to immune activation, the
recruitment of cytotoxic T cells and additional tumor cell
death 2) several cytotoxic chemotherapy agents have
been shown to promote “immunogenic cell death” and
3) systemic therapies can inﬂuence the immune micro-
environment, i.e. gemcitabine can suppress negative
immune regulators (3-5). In preclinical experiments,
chemotherapy plus PD-1, PDL-1 or CTLA-4 inhibitors
have demonstrated enhanced antitumor activity leading
to their evaluation in patients. Several phase I clinical
trials combining immune checkpoint inhibitors with a
variety of platinum based doublet have shown the
combination regimens are safe and tolerable (6-8).
Objective response rates and progression free survival
were favorable. As a result, numerous randomized
phase III trials comparing platinum doublets with or
without an immune checkpoint inhibitor are underway.
Combinations with molecularly targeted agents. The
rationale for pursuing these dual regimens is also based
on the release of neoantigens that occurs upon cell death
with effective targeted therapy (3,4). In addition
targeted therapies have been shown to remodel the
immune microenviroment. For example EGFR TKIs can
decrease PD-L1 expression and lead to tumor
regression in EGRF driven animal models (9). One
